lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry
Open Access
- 24 August 2024
- journal article
- research article
- Published by Springer Nature in Targeted Oncology
- Vol. 19 (5) , 735-745
Abstract
Background Patient demographics and shared decision making might influence the choice of adjuvant therapy for stage III melanoma. Objective To identify factors for treatment selection of patients diagnosed with stage III melanoma to better understand current treatment decisions and improve further treatment counseling. Patients and Methods Data from 2007 patients diagnosed with stage III melanoma, between December 2018 and 2021, sourced from the Dutch Cancer Registry, were analyzed. Results Among the cohort, 48.7% received no therapy, 45.8% received checkpoint inhibition, and 5.5% received targeted therapy (TT). Patients foregoing therapy were significantly older [67.0 years (range 53.0–77.0) vs. 62.0 year (range 52.0–72.0)], had poorer performance scores (PS), and higher Charlson Comorbidity Index scores compared to those receiving therapy (p < 0.001). Patients undergoing therapy had significantly higher median Breslow thickness (3.3 mm vs. 2.2 mm) and higher prevalence of ulceration (49.9% vs. 38.1%). Those with connective tissue disease and/or congestive heart disease were more likely to receive TT [odds ration (OR) 8.1; 95% confidence interval (CI) 1.7–37.6 and OR 9.3; 95% CI 1.2–72.2, respectively]. Median treatment time among strata for disease recurrence was 4.26 months (3.69–4.82) for immunotherapy and 3.1 months (0.85–5.36) for TT (p = 0.298). Patients who developed recurrent disease were equal across treatment types (p = 0.656). The number of patients with grade 3 complications was different for each treatment type [immunotherapy: 17.8% vs. TT: 37.3% (p < 0.001)]. Conclusions Age, PS, and Breslow thickness seem to influence adjuvant treatment decisions. Clinicians’ preference for immunotherapy might play a role in counseling BRAF-positive patients for adjuvant therapy, this however, cannot be confirmed in this dataset. Overall, only a small proportion of patients completed adjuvant treatment.Keywords
This publication has 38 references indexed in Scilit:
- Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021eClinicalMedicine, 2024
- Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profileEuropean Journal of Cancer, 2023
- Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyEuropean Journal of Cancer, 2023
- Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysisJournal of the American Academy of Dermatology, 2022
- The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness)Journal of the American Academy of Dermatology, 2022
- Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment RegistryJournal of Geriatric Oncology, 2021
- Adjuvant Treatment of Melanoma: Recent Developments and Future PerspectivesAmerican Journal of Clinical Dermatology, 2019
- A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable MelanomaClinical Oncology, 2018
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityEuropean Journal of Cancer, 2017
- Performance Status in Patients With CancerJAMA Oncology, 2015